20.500.12556/DiRROS-30930 The endocannabinoid system in neuropsychiatric disorders mechanisms, dysregulation and therapeutic potential The endocannabinoid system in neuropsychiatric disorders: mechanisms, dysregulation and therapeutic potential The endocannabinoid system (ECS) is a fundamental regulator of brain and body homeostasis, integrating neural, immune, and stress-related signaling pathways. Dysregulation of ECS components, including cannabinoid receptors (CB1 and CB2), endocannabinoids such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes (FAAH and MAGL), has been increasingly implicated in the pathophysiology of neuropsychiatric disorders, including mood, anxiety, psychotic, stress-related, and eating disorders. Altered endocannabinoid signaling contributes to maladaptive stress responses, emotional dysregulation, and impaired synaptic plasticity, highlighting the role of the ECS as a core integrative mechanism. Therapeutic strategies targeting ECS, particularly through FAAH inhibition and the use of plant-derived cannabinoids, such as cannabidiol (CBD), show promise in restoring endogenous homeostasis while minimizing the adverse cognitive and affective effects associated with direct CB1 activation. ECS function and treatment response are further influenced by genetic polymorphisms in CNR1, CNR2, FAAH, and MGLL, as well as epigenetic mechanisms, including DNA methylation, histone modifications, and microRNA regulation. Despite these advances, clinical translation remains limited by interindividual variability, the complexity of ECS interactions, and the relatively small size of existing clinical studies. Future research integrating longitudinal clinical trials with multi-omics approaches is essential to support the development of evidence-based, personalized interventions. Overall, understanding ECS mechanisms and dysregulation provides a valuable framework for the development of targeted therapies in neuropsychiatric disorders. endocannabinoid system cannabinoid receptors anandamide 2-arachidonoylglycerol neuropsychiatric disorders stress-related response mood disorders eating disorders ECS gene polymorphism ECS epigenetic modulation true false true Angleški jezik Ni določen Neznano 2026-07-08 16:32:22 2026-07-08 16:32:23 2026-07-09 03:57:03 0000-00-00 00:00:00 2026 0 0 Nasl. z nasl. zaslona; Opis vira z dne 24. 6. 2026; str. [1]-27 art. 968 iss. 5 May 2026 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 2026-05-01 577.2 2227-9059 10.3390/biomedicines14050968 282737923 https://doi.org/10.3390/biomedicines14050968 1 d688c830-7ad9-11f1-b663-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=47533 RAZ_Music_Timur_2026.pdf RAZ_Music_Timur_2026.pdf 1 4A8A4C770746EB41DD23580E5A029B30 3ffee44099ea4772ec13be81f2c2983655670bf68c4fba2b3aae1202a14ed60d 2f7d542a-7ada-11f1-b663-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=47534 Nacionalni inštitut za biologijo 0 0 0